Kathryn Colborn
Concepts (460)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Health Records | 14 | 2025 | 1174 | 3.960 |
Why?
| | Postoperative Complications | 34 | 2026 | 2939 | 2.950 |
Why?
| | Machine Learning | 11 | 2026 | 587 | 2.280 |
Why?
| | Surgical Wound Infection | 8 | 2025 | 329 | 1.830 |
Why?
| | Models, Statistical | 6 | 2026 | 675 | 1.590 |
Why?
| | Sepsis | 7 | 2025 | 642 | 1.340 |
Why?
| | Urinary Tract Infections | 4 | 2025 | 206 | 1.340 |
Why?
| | Surgical Procedures, Operative | 6 | 2025 | 268 | 1.320 |
Why?
| | Shock, Septic | 5 | 2025 | 216 | 1.310 |
Why?
| | Pancreatic Neoplasms | 11 | 2025 | 919 | 1.210 |
Why?
| | Quality Improvement | 14 | 2023 | 1287 | 1.160 |
Why?
| | Malaria | 4 | 2023 | 73 | 1.000 |
Why?
| | Law Enforcement | 1 | 2025 | 48 | 0.900 |
Why?
| | Retrospective Studies | 51 | 2026 | 17104 | 0.900 |
Why?
| | Police | 1 | 2025 | 45 | 0.890 |
Why?
| | Quality of Life | 13 | 2026 | 3180 | 0.860 |
Why?
| | Humans | 139 | 2026 | 144298 | 0.850 |
Why?
| | Databases, Factual | 16 | 2025 | 1489 | 0.730 |
Why?
| | Risk Assessment | 20 | 2026 | 3680 | 0.730 |
Why?
| | Postoperative Hemorrhage | 2 | 2023 | 104 | 0.730 |
Why?
| | Pneumonia | 4 | 2025 | 627 | 0.720 |
Why?
| | Malaria, Falciparum | 2 | 2018 | 33 | 0.710 |
Why?
| | Palliative Care | 10 | 2026 | 1008 | 0.690 |
Why?
| | Emergency Service, Hospital | 5 | 2025 | 2321 | 0.680 |
Why?
| | Plasmodium vivax | 2 | 2018 | 6 | 0.640 |
Why?
| | Pain | 2 | 2023 | 781 | 0.640 |
Why?
| | Malaria, Vivax | 2 | 2018 | 4 | 0.640 |
Why?
| | Middle Aged | 46 | 2026 | 35892 | 0.620 |
Why?
| | Adenocarcinoma | 5 | 2024 | 919 | 0.610 |
Why?
| | Aged | 38 | 2026 | 25901 | 0.610 |
Why?
| | Female | 68 | 2026 | 78137 | 0.600 |
Why?
| | Preoperative Care | 5 | 2026 | 378 | 0.580 |
Why?
| | Male | 61 | 2026 | 72263 | 0.580 |
Why?
| | Patient Reported Outcome Measures | 7 | 2024 | 496 | 0.580 |
Why?
| | Surgeons | 4 | 2025 | 341 | 0.560 |
Why?
| | Breast Neoplasms | 7 | 2024 | 2363 | 0.550 |
Why?
| | Inpatients | 4 | 2023 | 545 | 0.550 |
Why?
| | Artificial Intelligence | 1 | 2023 | 381 | 0.540 |
Why?
| | Poisson Distribution | 1 | 2018 | 78 | 0.530 |
Why?
| | Plasmodium falciparum | 1 | 2018 | 39 | 0.530 |
Why?
| | Thoracic Surgery | 3 | 2025 | 144 | 0.530 |
Why?
| | Health Plan Implementation | 1 | 2019 | 141 | 0.530 |
Why?
| | Risk Factors | 26 | 2026 | 10783 | 0.510 |
Why?
| | Neoadjuvant Therapy | 8 | 2024 | 461 | 0.510 |
Why?
| | Mosquito Control | 2 | 2023 | 29 | 0.490 |
Why?
| | Hospitalization | 7 | 2025 | 2440 | 0.490 |
Why?
| | Adult | 41 | 2025 | 40408 | 0.490 |
Why?
| | Algorithms | 5 | 2025 | 1839 | 0.460 |
Why?
| | Mosquito Nets | 1 | 2015 | 2 | 0.450 |
Why?
| | Child, Preschool | 19 | 2026 | 11767 | 0.450 |
Why?
| | Anopheles | 1 | 2015 | 18 | 0.450 |
Why?
| | Carcinoma, Pancreatic Ductal | 3 | 2023 | 292 | 0.430 |
Why?
| | Drug Prescriptions | 3 | 2021 | 283 | 0.410 |
Why?
| | Risk Adjustment | 2 | 2025 | 85 | 0.410 |
Why?
| | Extracorporeal Membrane Oxygenation | 3 | 2023 | 383 | 0.410 |
Why?
| | Thoracic Surgical Procedures | 2 | 2025 | 95 | 0.370 |
Why?
| | Mastectomy, Segmental | 2 | 2024 | 107 | 0.370 |
Why?
| | Ambulatory Surgical Procedures | 2 | 2023 | 79 | 0.360 |
Why?
| | Primary Health Care | 3 | 2025 | 1728 | 0.360 |
Why?
| | Patient Discharge | 2 | 2020 | 985 | 0.360 |
Why?
| | Hospital Mortality | 1 | 2016 | 1028 | 0.350 |
Why?
| | Decision Support Systems, Clinical | 2 | 2026 | 267 | 0.340 |
Why?
| | Hospice and Palliative Care Nursing | 2 | 2023 | 113 | 0.330 |
Why?
| | Robotic Surgical Procedures | 2 | 2024 | 182 | 0.330 |
Why?
| | Infant | 14 | 2026 | 10011 | 0.330 |
Why?
| | Mastectomy | 4 | 2024 | 174 | 0.320 |
Why?
| | Influenza, Human | 3 | 2021 | 616 | 0.310 |
Why?
| | Incidence | 8 | 2023 | 2886 | 0.310 |
Why?
| | Hospitals | 4 | 2025 | 727 | 0.300 |
Why?
| | Emergency Treatment | 2 | 2021 | 124 | 0.300 |
Why?
| | Opioid-Related Disorders | 1 | 2018 | 601 | 0.300 |
Why?
| | Zebrafish | 2 | 2025 | 528 | 0.300 |
Why?
| | Pancreatectomy | 4 | 2025 | 285 | 0.300 |
Why?
| | Heart Failure | 5 | 2025 | 2323 | 0.290 |
Why?
| | Colorado | 9 | 2025 | 4554 | 0.290 |
Why?
| | United States | 20 | 2025 | 15979 | 0.280 |
Why?
| | Aged, 80 and over | 11 | 2025 | 8265 | 0.280 |
Why?
| | Research Design | 3 | 2022 | 1128 | 0.270 |
Why?
| | Cohort Studies | 11 | 2024 | 5948 | 0.260 |
Why?
| | Longitudinal Studies | 5 | 2026 | 2940 | 0.260 |
Why?
| | Adolescent | 16 | 2026 | 22370 | 0.260 |
Why?
| | Osteoarthritis, Knee | 2 | 2021 | 279 | 0.260 |
Why?
| | Logistic Models | 5 | 2023 | 2112 | 0.260 |
Why?
| | Preoperative Period | 2 | 2025 | 149 | 0.250 |
Why?
| | Chagas Disease | 2 | 2018 | 42 | 0.250 |
Why?
| | Asthma | 1 | 2019 | 1770 | 0.250 |
Why?
| | Patient Satisfaction | 4 | 2024 | 706 | 0.250 |
Why?
| | Seasons | 3 | 2025 | 555 | 0.250 |
Why?
| | Proportional Hazards Models | 3 | 2026 | 1322 | 0.250 |
Why?
| | Child | 16 | 2026 | 22562 | 0.250 |
Why?
| | Cardiac Surgical Procedures | 2 | 2023 | 606 | 0.250 |
Why?
| | Autism Spectrum Disorder | 2 | 2023 | 410 | 0.250 |
Why?
| | Prognosis | 10 | 2024 | 4293 | 0.240 |
Why?
| | Mass Drug Administration | 3 | 2023 | 7 | 0.240 |
Why?
| | Rectal Neoplasms | 2 | 2019 | 158 | 0.240 |
Why?
| | Bayes Theorem | 2 | 2026 | 425 | 0.240 |
Why?
| | Arthroplasty, Replacement, Knee | 2 | 2021 | 371 | 0.230 |
Why?
| | Varenicline | 1 | 2025 | 28 | 0.230 |
Why?
| | Markov Chains | 1 | 2026 | 130 | 0.230 |
Why?
| | Monte Carlo Method | 1 | 2026 | 153 | 0.230 |
Why?
| | Survival Analysis | 2 | 2026 | 1368 | 0.230 |
Why?
| | Tobacco Use Cessation | 1 | 2025 | 28 | 0.230 |
Why?
| | Intracranial Pressure | 1 | 2026 | 65 | 0.220 |
Why?
| | Time-to-Treatment | 2 | 2025 | 242 | 0.220 |
Why?
| | Chemotherapy, Adjuvant | 5 | 2024 | 425 | 0.220 |
Why?
| | Elective Surgical Procedures | 2 | 2024 | 199 | 0.220 |
Why?
| | Craniofacial Abnormalities | 1 | 2025 | 77 | 0.220 |
Why?
| | CA-19-9 Antigen | 1 | 2024 | 34 | 0.210 |
Why?
| | Varicose Veins | 1 | 2024 | 16 | 0.210 |
Why?
| | Treatment Outcome | 13 | 2025 | 11713 | 0.210 |
Why?
| | Catheterization, Peripheral | 1 | 2025 | 119 | 0.210 |
Why?
| | Artemisinins | 2 | 2023 | 5 | 0.200 |
Why?
| | Heart Defects, Congenital | 2 | 2022 | 896 | 0.200 |
Why?
| | Metastasectomy | 1 | 2023 | 19 | 0.190 |
Why?
| | Specialties, Surgical | 2 | 2021 | 82 | 0.190 |
Why?
| | Hernia, Hiatal | 1 | 2023 | 39 | 0.190 |
Why?
| | Hypothermia | 1 | 2023 | 52 | 0.190 |
Why?
| | Multivariate Analysis | 2 | 2023 | 1537 | 0.190 |
Why?
| | Zebrafish Proteins | 2 | 2025 | 314 | 0.190 |
Why?
| | Endarterectomy, Carotid | 1 | 2023 | 60 | 0.190 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2023 | 36 | 0.190 |
Why?
| | Predictive Value of Tests | 4 | 2022 | 2113 | 0.190 |
Why?
| | Insecticides | 1 | 2023 | 42 | 0.190 |
Why?
| | MEF2 Transcription Factors | 1 | 2022 | 51 | 0.190 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2023 | 70 | 0.190 |
Why?
| | Europe | 1 | 2023 | 417 | 0.180 |
Why?
| | Ischemic Attack, Transient | 1 | 2023 | 71 | 0.180 |
Why?
| | Analgesics, Opioid | 3 | 2021 | 1142 | 0.180 |
Why?
| | Behavior Therapy | 1 | 2025 | 300 | 0.180 |
Why?
| | Practice Patterns, Physicians' | 3 | 2021 | 1359 | 0.180 |
Why?
| | Telemetry | 1 | 2022 | 40 | 0.180 |
Why?
| | Medication Therapy Management | 1 | 2023 | 72 | 0.180 |
Why?
| | Sentinel Lymph Node | 1 | 2022 | 49 | 0.180 |
Why?
| | Microcephaly | 1 | 2023 | 104 | 0.180 |
Why?
| | Young Adult | 11 | 2020 | 14092 | 0.180 |
Why?
| | Nervous System Diseases | 1 | 2025 | 283 | 0.180 |
Why?
| | Syncope | 1 | 2022 | 55 | 0.180 |
Why?
| | Carotid Stenosis | 1 | 2023 | 102 | 0.180 |
Why?
| | Polypharmacy | 1 | 2023 | 94 | 0.180 |
Why?
| | Quinolines | 2 | 2023 | 192 | 0.180 |
Why?
| | Anti-Bacterial Agents | 4 | 2025 | 1920 | 0.180 |
Why?
| | Hospitals, Pediatric | 1 | 2025 | 557 | 0.180 |
Why?
| | Information Dissemination | 1 | 2024 | 222 | 0.180 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2019 | 44 | 0.180 |
Why?
| | Galectins | 1 | 2022 | 27 | 0.180 |
Why?
| | Drug Hypersensitivity | 1 | 2023 | 89 | 0.180 |
Why?
| | Pneumonectomy | 1 | 2023 | 167 | 0.180 |
Why?
| | Smoking Cessation | 1 | 2025 | 436 | 0.170 |
Why?
| | Ivermectin | 1 | 2021 | 14 | 0.170 |
Why?
| | Mozambique | 2 | 2018 | 7 | 0.170 |
Why?
| | Delirium | 1 | 2023 | 104 | 0.170 |
Why?
| | Computer Simulation | 1 | 2026 | 1017 | 0.170 |
Why?
| | Neuroendocrine Tumors | 1 | 2023 | 113 | 0.170 |
Why?
| | Precision Medicine | 1 | 2025 | 453 | 0.170 |
Why?
| | Program Evaluation | 3 | 2021 | 941 | 0.160 |
Why?
| | Dysbiosis | 1 | 2022 | 187 | 0.160 |
Why?
| | Oxycodone | 1 | 2021 | 53 | 0.160 |
Why?
| | New Guinea | 2 | 2018 | 3 | 0.160 |
Why?
| | Surgery Department, Hospital | 1 | 2020 | 22 | 0.160 |
Why?
| | Vascular Surgical Procedures | 1 | 2024 | 342 | 0.160 |
Why?
| | Internet | 1 | 2025 | 698 | 0.160 |
Why?
| | Ambulatory Care | 1 | 2025 | 603 | 0.160 |
Why?
| | Communication | 2 | 2025 | 968 | 0.160 |
Why?
| | Knee Joint | 2 | 2021 | 426 | 0.160 |
Why?
| | Gastric Bypass | 1 | 2022 | 126 | 0.160 |
Why?
| | Adaptation, Psychological | 1 | 2025 | 713 | 0.160 |
Why?
| | Arthroplasty | 1 | 2020 | 59 | 0.160 |
Why?
| | Hypersensitivity | 1 | 2023 | 251 | 0.160 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 47 | 0.150 |
Why?
| | Qualitative Research | 2 | 2025 | 1660 | 0.150 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2025 | 1739 | 0.150 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2022 | 248 | 0.150 |
Why?
| | Faculty | 1 | 2021 | 153 | 0.150 |
Why?
| | Phenotype | 2 | 2025 | 3139 | 0.150 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1955 | 0.150 |
Why?
| | Brain Injuries, Traumatic | 1 | 2026 | 450 | 0.150 |
Why?
| | Terminal Care | 1 | 2023 | 282 | 0.150 |
Why?
| | Antimalarials | 1 | 2019 | 35 | 0.150 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2019 | 142 | 0.150 |
Why?
| | Telemedicine | 2 | 2025 | 957 | 0.150 |
Why?
| | Anti-Infective Agents | 1 | 2022 | 241 | 0.150 |
Why?
| | Latent Tuberculosis | 1 | 2010 | 71 | 0.150 |
Why?
| | Waiting Lists | 2 | 2021 | 263 | 0.150 |
Why?
| | Prisons | 1 | 2010 | 84 | 0.150 |
Why?
| | Intensive Care Units | 2 | 2022 | 912 | 0.140 |
Why?
| | Vaccination | 2 | 2025 | 1416 | 0.140 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 87 | 0.140 |
Why?
| | Aftercare | 1 | 2020 | 222 | 0.140 |
Why?
| | Laparoscopy | 1 | 2023 | 475 | 0.140 |
Why?
| | Organ Transplantation | 1 | 2021 | 247 | 0.140 |
Why?
| | Venous Thromboembolism | 1 | 2023 | 325 | 0.140 |
Why?
| | Datasets as Topic | 1 | 2019 | 119 | 0.140 |
Why?
| | Education, Medical, Undergraduate | 1 | 2021 | 205 | 0.140 |
Why?
| | Practice Guidelines as Topic | 2 | 2024 | 1565 | 0.140 |
Why?
| | Healthcare Disparities | 3 | 2025 | 732 | 0.140 |
Why?
| | Patient Acceptance of Health Care | 1 | 2025 | 880 | 0.140 |
Why?
| | Prospective Studies | 7 | 2026 | 7972 | 0.140 |
Why?
| | Social Marketing | 1 | 2008 | 15 | 0.140 |
Why?
| | Ventricular Function | 1 | 2018 | 54 | 0.140 |
Why?
| | Hospitals, University | 1 | 2018 | 176 | 0.140 |
Why?
| | Soft Tissue Infections | 1 | 2008 | 39 | 0.140 |
Why?
| | Developed Countries | 1 | 2018 | 38 | 0.140 |
Why?
| | General Surgery | 1 | 2021 | 206 | 0.140 |
Why?
| | Community Participation | 1 | 2019 | 122 | 0.140 |
Why?
| | Outpatients | 1 | 2022 | 444 | 0.140 |
Why?
| | Triage | 1 | 2021 | 249 | 0.140 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 438 | 0.140 |
Why?
| | Defibrillators, Implantable | 1 | 2022 | 381 | 0.140 |
Why?
| | Computers, Handheld | 1 | 2018 | 26 | 0.130 |
Why?
| | Reproductive Medicine | 1 | 2008 | 17 | 0.130 |
Why?
| | Population Groups | 1 | 2018 | 56 | 0.130 |
Why?
| | Obesity, Morbid | 1 | 2022 | 288 | 0.130 |
Why?
| | Rural Population | 2 | 2020 | 654 | 0.130 |
Why?
| | Herpesvirus 4, Human | 1 | 2019 | 176 | 0.130 |
Why?
| | Autistic Disorder | 1 | 2020 | 211 | 0.130 |
Why?
| | Climate | 1 | 2018 | 90 | 0.130 |
Why?
| | Cognition | 2 | 2023 | 1262 | 0.130 |
Why?
| | Sentinel Surveillance | 1 | 2017 | 46 | 0.130 |
Why?
| | Geography | 1 | 2018 | 203 | 0.130 |
Why?
| | Condoms | 1 | 2008 | 101 | 0.130 |
Why?
| | Patient Admission | 1 | 2019 | 219 | 0.130 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2019 | 101 | 0.130 |
Why?
| | Immunoglobulin A | 1 | 2019 | 214 | 0.130 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2023 | 117 | 0.130 |
Why?
| | ROC Curve | 1 | 2019 | 615 | 0.130 |
Why?
| | Burns | 1 | 2022 | 369 | 0.130 |
Why?
| | Safety-net Providers | 1 | 2019 | 128 | 0.130 |
Why?
| | Patient Compliance | 1 | 2021 | 587 | 0.130 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 338 | 0.130 |
Why?
| | Recovery of Function | 1 | 2021 | 715 | 0.130 |
Why?
| | Occupational Health | 1 | 2010 | 210 | 0.130 |
Why?
| | Lymph Node Excision | 3 | 2023 | 173 | 0.130 |
Why?
| | Gastroenteritis | 1 | 2017 | 63 | 0.130 |
Why?
| | Epidemics | 1 | 2018 | 98 | 0.130 |
Why?
| | Substance Abuse, Intravenous | 1 | 2008 | 127 | 0.130 |
Why?
| | Cell Phone | 1 | 2017 | 82 | 0.120 |
Why?
| | Anxiety Disorders | 1 | 2010 | 370 | 0.120 |
Why?
| | Influenza Vaccines | 1 | 2021 | 530 | 0.120 |
Why?
| | Radiotherapy, Conformal | 1 | 2016 | 74 | 0.120 |
Why?
| | HIV Infections | 2 | 2025 | 3148 | 0.120 |
Why?
| | Students, Medical | 1 | 2021 | 373 | 0.120 |
Why?
| | Membrane Glycoproteins | 1 | 2019 | 495 | 0.120 |
Why?
| | Parents | 1 | 2025 | 1393 | 0.120 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2017 | 103 | 0.120 |
Why?
| | Occupational Exposure | 1 | 2010 | 353 | 0.120 |
Why?
| | Fever | 1 | 2017 | 313 | 0.120 |
Why?
| | Forecasting | 1 | 2018 | 391 | 0.120 |
Why?
| | Melanoma | 1 | 2022 | 757 | 0.120 |
Why?
| | Patient Readmission | 2 | 2020 | 762 | 0.120 |
Why?
| | Alcoholism | 1 | 2023 | 813 | 0.120 |
Why?
| | Nurse Practitioners | 1 | 2018 | 138 | 0.120 |
Why?
| | Models, Organizational | 1 | 2016 | 143 | 0.120 |
Why?
| | Morbidity | 3 | 2022 | 322 | 0.120 |
Why?
| | Follow-Up Studies | 5 | 2024 | 5404 | 0.110 |
Why?
| | Cystic Fibrosis | 1 | 2025 | 1161 | 0.110 |
Why?
| | Skin Neoplasms | 1 | 2022 | 848 | 0.110 |
Why?
| | Humidity | 1 | 2015 | 52 | 0.110 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2023 | 888 | 0.110 |
Why?
| | Mobile Applications | 1 | 2017 | 197 | 0.110 |
Why?
| | Antibodies, Viral | 1 | 2019 | 671 | 0.110 |
Why?
| | Diarrhea | 3 | 2023 | 192 | 0.110 |
Why?
| | Massage | 2 | 2010 | 42 | 0.110 |
Why?
| | Mass Screening | 2 | 2020 | 1347 | 0.110 |
Why?
| | Family Practice | 1 | 2018 | 402 | 0.110 |
Why?
| | Pandemics | 4 | 2025 | 1693 | 0.100 |
Why?
| | Advance Care Planning | 1 | 2018 | 243 | 0.100 |
Why?
| | Cannabidiol | 1 | 2016 | 137 | 0.100 |
Why?
| | Anticonvulsants | 1 | 2016 | 242 | 0.100 |
Why?
| | Time Factors | 5 | 2024 | 7128 | 0.100 |
Why?
| | Stroke | 1 | 2023 | 1259 | 0.100 |
Why?
| | Neoplasms | 2 | 2025 | 2860 | 0.100 |
Why?
| | Indians, North American | 1 | 2009 | 597 | 0.100 |
Why?
| | Survival Rate | 3 | 2024 | 2081 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 1990 | 0.100 |
Why?
| | Models, Biological | 1 | 2021 | 1807 | 0.100 |
Why?
| | Parasitemia | 1 | 2013 | 15 | 0.100 |
Why?
| | Emergency Medical Services | 1 | 2021 | 694 | 0.100 |
Why?
| | Atrial Fibrillation | 1 | 2020 | 551 | 0.100 |
Why?
| | Environmental Exposure | 1 | 2018 | 573 | 0.100 |
Why?
| | Research | 1 | 2016 | 430 | 0.100 |
Why?
| | Chronic Pain | 1 | 2018 | 289 | 0.100 |
Why?
| | Myocardial Infarction | 1 | 2020 | 1209 | 0.090 |
Why?
| | Software | 1 | 2018 | 689 | 0.090 |
Why?
| | Medicaid | 1 | 2017 | 464 | 0.090 |
Why?
| | Surveys and Questionnaires | 5 | 2025 | 6035 | 0.090 |
Why?
| | Heart-Assist Devices | 1 | 2018 | 568 | 0.090 |
Why?
| | Diagnostic Tests, Routine | 2 | 2024 | 107 | 0.090 |
Why?
| | Axilla | 2 | 2023 | 51 | 0.090 |
Why?
| | Temperature | 1 | 2015 | 675 | 0.090 |
Why?
| | Emergencies | 2 | 2025 | 174 | 0.090 |
Why?
| | Washington | 2 | 2025 | 147 | 0.090 |
Why?
| | Epilepsy | 1 | 2016 | 386 | 0.090 |
Why?
| | Feedback | 2 | 2023 | 181 | 0.090 |
Why?
| | Patients | 2 | 2023 | 181 | 0.090 |
Why?
| | Multicenter Studies as Topic | 2 | 2023 | 408 | 0.090 |
Why?
| | Age Factors | 4 | 2021 | 3324 | 0.080 |
Why?
| | Prevalence | 3 | 2023 | 2836 | 0.080 |
Why?
| | Uganda | 2 | 2023 | 92 | 0.080 |
Why?
| | Pain Management | 2 | 2010 | 407 | 0.080 |
Why?
| | Disease Progression | 1 | 2019 | 2844 | 0.080 |
Why?
| | Lymphatic Metastasis | 2 | 2023 | 330 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2917 | 0.080 |
Why?
| | Neoplasm Staging | 2 | 2025 | 1460 | 0.080 |
Why?
| | Heart Transplantation | 1 | 2017 | 673 | 0.080 |
Why?
| | Internship and Residency | 1 | 2021 | 1261 | 0.080 |
Why?
| | Laboratories | 2 | 2021 | 109 | 0.080 |
Why?
| | Postoperative Period | 2 | 2021 | 350 | 0.080 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 2194 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2643 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2016 | 942 | 0.070 |
Why?
| | Guatemala | 2 | 2023 | 344 | 0.070 |
Why?
| | Societies, Medical | 2 | 2024 | 890 | 0.070 |
Why?
| | Administration, Oral | 2 | 2025 | 847 | 0.070 |
Why?
| | Lymph Nodes | 2 | 2023 | 500 | 0.070 |
Why?
| | Feeding Behavior | 1 | 2015 | 686 | 0.070 |
Why?
| | Anti-HIV Agents | 1 | 2016 | 890 | 0.070 |
Why?
| | Piperazines | 2 | 2023 | 378 | 0.070 |
Why?
| | Biomedical Research | 2 | 2025 | 712 | 0.070 |
Why?
| | Guideline Adherence | 2 | 2024 | 586 | 0.070 |
Why?
| | Immunization Programs | 1 | 2009 | 193 | 0.060 |
Why?
| | Echocardiography | 2 | 2022 | 644 | 0.060 |
Why?
| | Comorbidity | 2 | 2022 | 1652 | 0.060 |
Why?
| | School Health Services | 1 | 2009 | 221 | 0.060 |
Why?
| | Urban Population | 2 | 2020 | 493 | 0.060 |
Why?
| | Insurance Coverage | 2 | 2017 | 243 | 0.060 |
Why?
| | Referral and Consultation | 2 | 2023 | 850 | 0.060 |
Why?
| | Length of Stay | 2 | 2023 | 1338 | 0.060 |
Why?
| | Nebraska | 1 | 2025 | 21 | 0.060 |
Why?
| | Wyoming | 1 | 2025 | 27 | 0.060 |
Why?
| | Affect | 1 | 2008 | 322 | 0.060 |
Why?
| | India | 1 | 2025 | 219 | 0.060 |
Why?
| | Pilot Projects | 2 | 2023 | 1880 | 0.060 |
Why?
| | Administration, Intravenous | 1 | 2025 | 170 | 0.050 |
Why?
| | Glasgow Coma Scale | 1 | 2026 | 218 | 0.050 |
Why?
| | Cytokines | 2 | 2023 | 2043 | 0.050 |
Why?
| | Infant, Newborn | 3 | 2022 | 6387 | 0.050 |
Why?
| | Socioeconomic Factors | 2 | 2020 | 1320 | 0.050 |
Why?
| | Acute Disease | 2 | 2017 | 1029 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 5862 | 0.050 |
Why?
| | Propensity Score | 1 | 2026 | 371 | 0.050 |
Why?
| | Health Care Surveys | 2 | 2010 | 537 | 0.050 |
Why?
| | Body Mass Index | 2 | 2023 | 2417 | 0.050 |
Why?
| | Monitoring, Physiologic | 1 | 2026 | 288 | 0.050 |
Why?
| | Animals | 4 | 2025 | 37800 | 0.050 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2024 | 223 | 0.050 |
Why?
| | Motivational Interviewing | 1 | 2025 | 122 | 0.050 |
Why?
| | Multilocus Sequence Typing | 1 | 2022 | 17 | 0.050 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2023 | 133 | 0.050 |
Why?
| | Growth Disorders | 1 | 2023 | 86 | 0.050 |
Why?
| | Sternotomy | 1 | 2022 | 25 | 0.050 |
Why?
| | Herniorrhaphy | 1 | 2023 | 76 | 0.050 |
Why?
| | Biological Variation, Population | 1 | 2022 | 20 | 0.050 |
Why?
| | Health Facilities | 1 | 2023 | 86 | 0.050 |
Why?
| | Death | 1 | 2023 | 130 | 0.050 |
Why?
| | Cost-Benefit Analysis | 1 | 2025 | 637 | 0.050 |
Why?
| | Body Surface Area | 1 | 2022 | 34 | 0.050 |
Why?
| | Papua New Guinea | 1 | 2012 | 10 | 0.050 |
Why?
| | Vomiting | 1 | 2023 | 131 | 0.050 |
Why?
| | Burn Units | 1 | 2022 | 41 | 0.050 |
Why?
| | Breast | 1 | 2023 | 157 | 0.050 |
Why?
| | Alleles | 1 | 2025 | 881 | 0.050 |
Why?
| | Community Health Workers | 1 | 2023 | 86 | 0.050 |
Why?
| | Cough | 1 | 2023 | 123 | 0.050 |
Why?
| | Cardiology | 1 | 2025 | 359 | 0.040 |
Why?
| | Stroke Volume | 1 | 2025 | 650 | 0.040 |
Why?
| | Carotid Arteries | 1 | 2023 | 207 | 0.040 |
Why?
| | Patient Acuity | 1 | 2022 | 47 | 0.040 |
Why?
| | Neutrophil Infiltration | 1 | 2022 | 104 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2023 | 768 | 0.040 |
Why?
| | Demography | 1 | 2022 | 287 | 0.040 |
Why?
| | Educational Status | 1 | 2023 | 463 | 0.040 |
Why?
| | Neurosurgical Procedures | 1 | 2023 | 202 | 0.040 |
Why?
| | Inappropriate Prescribing | 1 | 2022 | 65 | 0.040 |
Why?
| | Sample Size | 1 | 2021 | 120 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 661 | 0.040 |
Why?
| | Habits | 1 | 2020 | 52 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2022 | 238 | 0.040 |
Why?
| | Research Personnel | 1 | 2022 | 184 | 0.040 |
Why?
| | Focus Groups | 1 | 2023 | 566 | 0.040 |
Why?
| | Gastrectomy | 1 | 2022 | 161 | 0.040 |
Why?
| | Censuses | 1 | 2020 | 35 | 0.040 |
Why?
| | Lung | 2 | 2024 | 4084 | 0.040 |
Why?
| | Policy | 1 | 2021 | 147 | 0.040 |
Why?
| | Schools, Medical | 1 | 2021 | 157 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 1263 | 0.040 |
Why?
| | Blood Proteins | 1 | 2022 | 233 | 0.040 |
Why?
| | Fear | 1 | 2023 | 366 | 0.040 |
Why?
| | South Africa | 1 | 2021 | 265 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2021 | 516 | 0.040 |
Why?
| | Reoperation | 1 | 2023 | 623 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2020 | 248 | 0.040 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2019 | 50 | 0.040 |
Why?
| | Urination Disorders | 1 | 2019 | 15 | 0.040 |
Why?
| | Epstein-Barr Virus Nuclear Antigens | 1 | 2019 | 12 | 0.040 |
Why?
| | Risk | 1 | 2022 | 910 | 0.040 |
Why?
| | Organoplatinum Compounds | 1 | 2019 | 66 | 0.040 |
Why?
| | Program Development | 1 | 2021 | 368 | 0.040 |
Why?
| | Mentors | 1 | 2021 | 214 | 0.040 |
Why?
| | Leucovorin | 1 | 2019 | 100 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 524 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2022 | 503 | 0.040 |
Why?
| | Kenya | 1 | 2019 | 127 | 0.040 |
Why?
| | Cardiovascular Nursing | 1 | 2018 | 5 | 0.030 |
Why?
| | Colombia | 1 | 2018 | 42 | 0.030 |
Why?
| | Survivors | 1 | 2022 | 518 | 0.030 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2019 | 156 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2010 | 267 | 0.030 |
Why?
| | Fluorouracil | 1 | 2019 | 234 | 0.030 |
Why?
| | Drug Combinations | 1 | 2019 | 392 | 0.030 |
Why?
| | Hospitals, Veterans | 1 | 2009 | 258 | 0.030 |
Why?
| | Patient-Centered Care | 1 | 2023 | 540 | 0.030 |
Why?
| | Range of Motion, Articular | 1 | 2020 | 423 | 0.030 |
Why?
| | Overweight | 1 | 2023 | 606 | 0.030 |
Why?
| | Chronic Disease | 1 | 2024 | 1809 | 0.030 |
Why?
| | Rectum | 1 | 2019 | 183 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2024 | 1314 | 0.030 |
Why?
| | Coinfection | 1 | 2019 | 141 | 0.030 |
Why?
| | Odds Ratio | 1 | 2010 | 1076 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2021 | 574 | 0.030 |
Why?
| | Mortality | 1 | 2019 | 376 | 0.030 |
Why?
| | Proctitis | 1 | 2016 | 6 | 0.030 |
Why?
| | Caregivers | 1 | 2025 | 1051 | 0.030 |
Why?
| | Urogenital System | 1 | 2016 | 17 | 0.030 |
Why?
| | Critical Illness | 1 | 2023 | 886 | 0.030 |
Why?
| | Viral Load | 1 | 2019 | 527 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 1143 | 0.030 |
Why?
| | Latin America | 1 | 2016 | 95 | 0.030 |
Why?
| | Prisoners | 1 | 2008 | 143 | 0.030 |
Why?
| | Mental Health | 1 | 2023 | 790 | 0.030 |
Why?
| | Weight Loss | 1 | 2022 | 838 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2018 | 355 | 0.030 |
Why?
| | Population Surveillance | 1 | 2019 | 483 | 0.030 |
Why?
| | Sexually Transmitted Diseases | 1 | 2008 | 162 | 0.030 |
Why?
| | Medically Uninsured | 1 | 2017 | 129 | 0.030 |
Why?
| | Radiotherapy Dosage | 1 | 2016 | 288 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 1114 | 0.030 |
Why?
| | Health Status | 1 | 2021 | 833 | 0.030 |
Why?
| | Radiation Injuries | 1 | 2016 | 149 | 0.030 |
Why?
| | Self Care | 1 | 2018 | 388 | 0.030 |
Why?
| | Plant Extracts | 1 | 2016 | 184 | 0.030 |
Why?
| | Electrocardiography | 1 | 2018 | 663 | 0.030 |
Why?
| | Public Health | 1 | 2019 | 563 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 845 | 0.030 |
Why?
| | Transcription Factors | 1 | 2022 | 1726 | 0.030 |
Why?
| | Mutation | 1 | 2025 | 4068 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 966 | 0.030 |
Why?
| | Curriculum | 1 | 2021 | 1063 | 0.030 |
Why?
| | Insurance, Health | 1 | 2017 | 308 | 0.030 |
Why?
| | Hemorrhage | 1 | 2019 | 807 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2020 | 3595 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3408 | 0.020 |
Why?
| | Sex Factors | 1 | 2018 | 2103 | 0.020 |
Why?
| | Health Promotion | 1 | 2008 | 771 | 0.020 |
Why?
| | Biomarkers | 1 | 2022 | 4248 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2862 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 3068 | 0.020 |
Why?
| | Registries | 1 | 2018 | 2389 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2008 | 318 | 0.020 |
Why?
| | Veterans | 1 | 2009 | 1614 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2009 | 1098 | 0.010 |
Why?
|
|
Colborn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|